Naoto Oku

Prof. Naoto Oku


Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2017 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
TFTatsuya Fukuta
Tatsuya Fukuta
TATomohiro Asai
Tomohiro Asai
YYYosuke Yanagida
Yosuke Yanagida
MNMio Namba
Mio Namba
HKHiroyuki Koide
Hiroyuki Koide
NONaoto Oku
Naoto Oku
For ischemic stroke treatment, extension of the therapeutic time window (TTW) of thrombolytic therapy with tissue plasminogen activator (tPA) and amelioration of secondary ischemia/reperfusion (I/R) injury are most desirable. Our previous studies have indicated that liposomal delivery of neuroprotectants into an ischemic region is effective for stroke treatment. In the present study, for solving the above problems in the clinical setting, the usefulness of combination therapy with tPA and liposomal fasudil (fasudil‐Lip) was investigated in ischemic stroke model rats with photochemically induced thrombosis, with clots that were dissolved by tPA. Treatment with tPA 3 h after occlusion markedly increased blood–brain barrier permeability and activated matrix metalloproteinase (MMP)‐2 and −9, which are involved in cerebral hemorrhage. However, an intravenous administration of fasudil‐Lip before tPA markedly suppressed the increase in permeability and the MMP activation stemming from tPA. The combination treatment showed significantly larger neuroprotective effects, even in the case of delayed tPA administration compared with each treatment alone or the tPA/fasudil‐treated group. These findings suggest that treatment with fasudil‐Lip before tPA could decrease the risk of tPA‐derived cerebral hemorrhage and extend the TTW of tPA and that the combination therapy could be a useful therapeutic option for ischemic stroke.—Fukuta, T., Asai, T., Yanagida, Y., Namba, M., Koide, H., Shimizu, K., Oku, N. Combination therapy with liposomal neuroprotectants and tissue plasminogen activator for treatment of ischemic stroke. FASEB J. 31, 1879–1890 (2017). www.fasebj.org

18 April 2002 in Oncogene
Verified
Journal Article
Closed access
NONaoto Oku
Naoto Oku
TATomohiro Asai
Tomohiro Asai
KWKoh Watanabe
Koh Watanabe
KKKoichi Kuromi
Koichi Kuromi
MNMayumi Nagatsuka
Mayumi Nagatsuka
TTTakao Taki
Takao Taki

22 February 2010 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
YKYasufumi Katanasaka
Yasufumi Katanasaka
TITakayuki Ishii
Takayuki Ishii
TATomohiro Asai
Tomohiro Asai
HNHirotaka Naitou
Hirotaka Naitou
NMNoriyuki Maeda
Noriyuki Maeda
NONaoto Oku
Naoto Oku
Angiogenesis is crucial for tumor growth and hematogenous metastasis. Specifically expressed and functional protein molecules in angiogenic endothelial cells, especially on the plasma membrane, may be molecular targets for antiangiogenic drugs and drug delivery systems (DDS) in cancer therapy. To discover such target molecules, we performed subcellular proteome analysis of human umbilical vein endothelial cells (HUVECs) treated with or without vascular endothelial growth factor (VEGF) using 2‐dimensional difference in‐gel electrophoresis (2D‐DIGE) and matrix‐assisted laser desorption/ionization tandem time‐of‐flight mass spectrometry (MALDI‐TOF/TOF‐MS). Among the identified proteins, BiP/GRP78, a molecular chaperone, was highly expressed in the membrane/organelle fraction of HUVECs after VEGF treatment. The involvement of BiP in VEGF‐induced angiogenesis was examined by RNA interference. BiP knockdown significantly suppressed VEGF‐induced endothelial cell proliferation and VEGF‐induced phosphorylation of extracellular‐regulated kinase 1/2, phospholipase C‐γ, and VEGF receptor‐2 in HUVECs. Cell surface biotinylation analysis revealed that the cell surface expression of BiP was elevated in VEGF‐activated HUVECs. Aiming to apply BiP to a target molecule in liposomal DDS, we developed liposomes modified with the WIFPWIQL peptide, which has been shown to bind to BiP, and investigated its potential for cancer therapy. The WIFPWIQL‐modified liposomes (WIFPWIQL liposomes) were significantly taken up by VEGF‐activated HUVECs as compared to peptide‐unmodified liposomes. WIFPWIQL liposomes appeared to accumulate in tumor endothelial cells in vivo . WIFPWIQL liposomes containing doxorubicin significantly suppressed tumor growth and prolonged the survival of colon26 NL‐17 carcinoma cell‐bearing mice. In summary, BiP may regulate VEGF‐induced endothelial cell proliferation through VEGFR‐2‐mediated signaling and be an effective target molecule for cancer antineovascular therapy.

14 December 2012 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
TITakayuki Ishii
Takayuki Ishii
TATomohiro Asai
Tomohiro Asai
DODai Oyama
Dai Oyama
YAYurika Agato
Yurika Agato
NYNodoka Yasuda
Nodoka Yasuda
NONaoto Oku
Naoto Oku
FK506 (Tacrolimus) has the potential to decrease cerebral ischemia‐reperfusion injury. However, the clinical trial of FK506 as a neuroprotectant failed due to adverse side effects. This present study aimed to conduct the selective delivery of FK506 to damaged regions, while at the same time reducing the dosage of FK506, by using a liposomal drug delivery system. First, the cytoprotective effect of polyethylene glycol‐modified liposomes encapsulating FK506 (FK506‐liposomes) on neuron‐like pheochromocytoma PC12 cells was examined. FK506‐liposomes protected these cells from H 2 O 2 ‐induced toxicity in a dose‐dependent manner. Next, we investigated the usefulness of FK506‐liposomes in transient middle cerebral artery occlusion (t‐MCAO) rats. FK506‐liposomes accumulated in the brain parenchyma by passing through the disrupted blood‐brain barrier at an early stage after reperfusion had been initiated. Histological analysis showed that FK506‐liposomes strongly suppressed neutrophil invasion and apoptotic cell death, events that lead to a poor stroke outcome. Corresponding to these results, a single injection of FK506‐liposomes at a low dosage significantly reduced cerebral cell death and ameliorated motor function deficits in t‐MCAO rats. These results suggest that liposomalization of FK506 could reduce the administration dose by enhancing the therapeutic efficacy; hence, FK506‐liposomes should be a promising neuroprotectant after cerebral stroke.—Ishii, T., Asai, T., Oyama, D., Agato, Y., Yasuda, N., Fukuta, T., Shimizu, K., Minamino, T., Oku, N. Treatment of cerebral ischemia‐reperfusion injury with PEGylated liposomes encapsulating FK506. FASEB J. 27, 1362–1370 (2013). www.fasebj.org

1 April 2014 in Brain Research
Verified
Journal Article
Closed access
NYNodoka Yasuda
Nodoka Yasuda
TITakayuki Ishii
Takayuki Ishii
DODai Oyama
Dai Oyama
TFTatsuya Fukuta
Tatsuya Fukuta
YAYurika Agato
Yurika Agato
NONaoto Oku
Naoto Oku

5 March 2018 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
AOAyaka Okamoto
Ayaka Okamoto
TATomohiro Asai
Tomohiro Asai
YHYusuke Hirai
Yusuke Hirai
KSKosuke Shimizu
Kosuke Shimizu
HKHiroyuki Koide
Hiroyuki Koide
NONaoto Oku
Naoto Oku